Our goal is to best translate the scientific discoveries in the fields of thrombosis, hemostasis, and vascular biology into the groundbreaking research and diagnostic products for improving patient treatments.
For nearly 30 years, I have studied the mechanisms of thrombus formation in a pharmaceutical company (the Chemo-Sero-Therapeutic Research Institute, Kumamoto) and academic institute (the Scripps Research Institute, La Jolla, California). I have recently unveiled the novel blood coagulaiton mechanism (Blood. 130:1661-1670, 2017). Based on the recent discovery, I have invented highly sensitive micro-assays of thrombin production (SMAT), a blood coagulation test.
To best translate the discovery into diagnostic products for patients (i.e., from benchside to bedside), I have founded the company “Thrombo Translational Research Lab Inc. (T-TRL)” in Kumamoto, Japan in October 2019.
To date, many studies performed by pioneer researchers have elucidated the mechanisms of thrombus formation: These include adhesion and activation of platelets, blood coagulation cascade reactions, and fibrinolytic system. Despite advancing our knowledge of thrombus formation, we are still lacking in innovative diagnostic approaches that allow early identification of abnormality in thrombus formation. For more safely treating patients with anti-thrombotic drug, novel blood coagulation test capable of precisely evaluation of bleeding risk is also needed.
The SMAT may provide novel approaches for precise evaluation of thrombus formation on an individualized basis for patients with thrombosis and bleeding. The assays also may offer promising tools for identifying and characterizing the new hemostatic and antithrombotic drugs with improved therapeutic efficacy.
We provide contract research services for supporting your drug discovery study and assisting you with designing research strategies, utilizing our state of art knowledge.
Finally, we are very happy if we would advance scientific discoveries in the areas of thrombosis, bleeding, infection, inflammation, and cancer, and provide patients with the most benefit for treating thrombotic and hemorrhagic disorders.
October 1st, 2020
Yuichi Kamikubo, Ph.D.
President and CEO
